You are here

  • Home
  • Archive
  • Volume 75, Issue Suppl 2
  • THU0615 Cost per Response for Abatacept Compared with Adalimumab in The Treatment of Patients with Rheumatoid Arthritis Based on anti-citrullinated Protein Antibody Titres in Italy, Spain and Canada

Citation Tools

Article menu
Download PDFPDF
Poster Presentations
Epidemiology, health services and outcome research
THU0615 Cost per Response for Abatacept Compared with Adalimumab in The Treatment of Patients with Rheumatoid Arthritis Based on anti-citrullinated Protein Antibody Titres in Italy, Spain and Canada

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Foo J, Mennini F, Rodriguez Heredia J, et al
THU0615 Cost per Response for Abatacept Compared with Adalimumab in The Treatment of Patients with Rheumatoid Arthritis Based on anti-citrullinated Protein Antibody Titres in Italy, Spain and Canada
Annals of the Rheumatic Diseases 2016;75:415.